Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra. Elarekibep can be used for the research of T2 endotype asthma[1].
in vivo
PRS-060 (i.t; 2, 10, 50 μg) inhibits IL-13-induced eotaxin-1 expression in the lung and ovalbumin-induced acute allergic inflammation in the humanized mouse[1].
Animal Model:
Triple-humanized mouse model[1]
Dosage:
2, 10, 50 μg/mouse
Administration:
Intratracheal instillation (i.t)
Result:
Strongly suppressed acute allergic inflammation indices in triple humanized mice.
References
[1] Gabriele Matschiner, et al. Elarekibep (PRS-060/AZD1402): a new class of inhaled Anticalin medicine targeting IL-4Ra for T2 endotype asthma. J Allergy Clin Immunol. 2022 Dec 30;S0091-6749(22)02588-X. DOI:10.1016/j.jaci.2022.12.815
